Trials / Terminated
TerminatedNCT00421317
Imatinib in Adult Patients With Metastatic Ocular Melanoma
A Phase II Multicentric Trial to Assess Efficacy and Toxicity of Imatinib in Adult Patients With Metastatic Ocular Melanoma
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- Centre Oscar Lambret · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The scope of the trial is to determinate the anti-tumoral activity of imatinib in metastatic ocular melanoma patients.
Detailed description
Further study details as provided by Centre Oscar Lambret
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Imatinib | 800 mg/day until disease progression or toxicity |
Timeline
- Start date
- 2005-12-01
- Primary completion
- 2009-11-15
- Completion
- 2009-11-15
- First posted
- 2007-01-11
- Last updated
- 2026-03-13
Locations
12 sites across 1 country: France
Source: ClinicalTrials.gov record NCT00421317. Inclusion in this directory is not an endorsement.